Eli Lilly EBITDA Margin 2010-2024 | LLY

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Eli Lilly (LLY) over the last 10 years. The current EBITDA margin for Eli Lilly as of March 31, 2024 is .
Eli Lilly EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-03-31 $35.93B $9.04B 25.16%
2023-12-31 $34.12B $7.99B 23.40%
2023-09-30 $32.07B $7.42B 23.13%
2023-06-30 $29.52B $8.60B 29.13%
2023-03-31 $27.69B $7.67B 27.68%
2022-12-31 $28.54B $8.65B 30.30%
2022-09-30 $29.24B $8.80B 30.10%
2022-06-30 $29.07B $9.03B 31.05%
2022-03-31 $29.32B $9.24B 31.51%
2021-12-31 $28.32B $7.91B 27.92%
2021-09-30 $27.76B $7.90B 28.47%
2021-06-30 $26.73B $7.28B 27.22%
2021-03-31 $25.49B $7.02B 27.56%
2020-12-31 $24.54B $7.38B 30.08%
2020-09-30 $23.21B $6.76B 29.13%
2020-06-30 $22.95B $6.85B 29.83%
2020-03-31 $23.09B $7.07B 30.62%
2019-12-31 $22.32B $6.21B 27.81%
2019-09-30 $21.84B $5.71B 26.15%
2019-06-30 $21.67B $5.75B 26.54%
2019-03-31 $21.62B $4.43B 20.47%
2018-12-31 $21.49B $5.14B 23.93%
2018-09-30 $19.12B $4.59B 24.00%
2018-06-30 $19.47B $3.75B 19.23%
2018-03-31 $19.71B $4.92B 24.97%
2017-12-31 $19.97B $3.57B 17.88%
2017-09-30 $22.47B $3.90B 17.37%
2017-06-30 $22.01B $4.33B 19.65%
2017-03-31 $21.59B $4.03B 18.65%
2016-12-31 $21.22B $4.76B 22.41%
2016-09-30 $20.84B $4.41B 21.14%
2016-06-30 $20.61B $4.39B 21.30%
2016-03-31 $20.18B $4.34B 21.49%
2015-12-31 $19.96B $4.12B 20.63%
2015-09-30 $19.71B $4.10B 20.78%
2015-06-30 $19.62B $3.72B 18.94%
2015-03-31 $19.58B $3.71B 18.93%
2014-12-31 $19.62B $4.04B 20.59%
2014-09-30 $20.30B $4.62B 22.76%
2014-06-30 $21.20B $5.57B 26.29%
2014-03-31 $22.20B $6.21B 27.96%
2013-12-31 $23.11B $6.82B 29.49%
2013-09-30 $23.26B $6.94B 29.84%
2013-06-30 $22.93B $6.56B 28.59%
2013-03-31 $22.60B $6.25B 27.67%
2012-12-31 $22.60B $6.20B 27.41%
2012-09-30 $22.69B $6.15B 27.11%
2012-06-30 $23.40B $6.59B 28.15%
2012-03-31 $24.05B $6.97B 28.97%
2011-12-31 $24.29B $6.90B 28.42%
2011-09-30 $24.43B $7.27B 29.74%
2011-06-30 $23.93B $7.42B 30.99%
2011-03-31 $23.43B $7.60B 32.44%
2010-12-31 $23.08B $7.86B 34.05%
2010-09-30 $22.82B $7.11B 31.15%
2010-06-30 $22.73B $7.01B 30.83%
2010-03-31 $22.28B $6.78B 30.46%
2009-12-31 $21.84B $6.89B 31.53%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $840.044B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $637.050B 48.95
Johnson & Johnson (JNJ) United States $357.994B 14.22
Merck (MRK) United States $331.088B 60.24
AbbVie (ABBV) United States $300.886B 15.55
AstraZeneca (AZN) United Kingdom $244.568B 21.26
Novartis AG (NVS) Switzerland $215.070B 15.25
Pfizer (PFE) United States $157.191B 19.53
Sanofi (SNY) $119.570B 11.27
Innoviva (INVA) United States $0.993B 6.97